within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BK02_Canagliflozin;

model Canagliflozin
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.65,
    Cl = 3.3888888888888884e-06,
    adminDuration = 600,
    adminMass = 300 / 1000000,
    adminCount = 1,
    Vd = 0.119,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.02,
    Tlag = 19.8,
    Vdp = 0.482,
    k12 = 1.883333333333333e-05,
    k21 = 1.883333333333333e-05);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Canagliflozin</td></tr><tr><td>ATC code:</td><td>A10BK02</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>300</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>119</td><td>L</td></tr>
    <tr><td>clearance:</td><td>12.2</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated for the treatment of type 2 diabetes mellitus in adults, improving glycemic control by reducing renal glucose reabsorption and promoting urinary glucose excretion. It is an approved, widely used oral antidiabetic agent.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers, both male and female, following a single 300 mg oral dose under fasting conditions.</p><h4>References</h4><ol><li><p>Chen, X, et al., &amp; Devineni, D (2015). Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Canagliflozin in Healthy Chinese Subjects. <i>Clinical therapeutics</i> 37(7) 1483–1492.e1. DOI:<a href=\"https://doi.org/10.1016/j.clinthera.2015.04.015\">10.1016/j.clinthera.2015.04.015</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26048186/\">https://pubmed.ncbi.nlm.nih.gov/26048186</a></p></li><li><p>Devineni, D, et al., &amp; Wajs, E (2016). Single-dose Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Selective Inhibitor of Sodium Glucose Cotransporter 2, in Healthy Indian Participants. <i>Clinical therapeutics</i> 38(1) 89–98.e1. DOI:<a href=\"https://doi.org/10.1016/j.clinthera.2015.11.008\">10.1016/j.clinthera.2015.11.008</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26687552/\">https://pubmed.ncbi.nlm.nih.gov/26687552</a></p></li><li><p>Devineni, D, et al., &amp; Wajs, E (2015). Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor. <i>Clinical therapeutics</i> 37(3) 610–628.e4. DOI:<a href=\"https://doi.org/10.1016/j.clinthera.2014.12.013\">10.1016/j.clinthera.2014.12.013</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25659911/\">https://pubmed.ncbi.nlm.nih.gov/25659911</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.A.A10BK02 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Canagliflozin;
